We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At 52 weeks, patients receiving dupilumab vs. placebo ...

Please provide your email address to receive an email when new articles are posted on . Incidence rates for cancers included 12.88 for the exposed group and 15.04 for the unexposed group. Adjusting ...

New research from Trinity College Dublin has documented the significant impact of severe eczema on a child's height and shown ...

Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...

For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA ...

Dupilumab, tezepelumab, and stapokibart may offer greater clinical benefits than other biologics for patients with severe CRSwNP.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...

In an exploratory analysis, dupilumab restored intraepidermal nerve fibre density (IENFD) in patients with moderate-to-severe atopic dermatitis (AD) to levels similar to those seen in healthy control ...